WO2011161226A3 - Novel antibody formulation - Google Patents

Novel antibody formulation Download PDF

Info

Publication number
WO2011161226A3
WO2011161226A3 PCT/EP2011/060589 EP2011060589W WO2011161226A3 WO 2011161226 A3 WO2011161226 A3 WO 2011161226A3 EP 2011060589 W EP2011060589 W EP 2011060589W WO 2011161226 A3 WO2011161226 A3 WO 2011161226A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody formulation
novel antibody
formulation
novel
preparation
Prior art date
Application number
PCT/EP2011/060589
Other languages
French (fr)
Other versions
WO2011161226A2 (en
Inventor
Michael Adler
Christine Wurth
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of WO2011161226A2 publication Critical patent/WO2011161226A2/en
Publication of WO2011161226A3 publication Critical patent/WO2011161226A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Pharmaceutical liquid formulation of an antibody against human OX40L, a process for the preparation and uses of the formulation.
PCT/EP2011/060589 2010-06-25 2011-06-24 Novel antibody formulation WO2011161226A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10167357.2 2010-06-25
EP10167357A EP2399604A1 (en) 2010-06-25 2010-06-25 Novel antibody formulation

Publications (2)

Publication Number Publication Date
WO2011161226A2 WO2011161226A2 (en) 2011-12-29
WO2011161226A3 true WO2011161226A3 (en) 2012-05-03

Family

ID=43037068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/060589 WO2011161226A2 (en) 2010-06-25 2011-06-24 Novel antibody formulation

Country Status (5)

Country Link
US (1) US20120128687A1 (en)
EP (1) EP2399604A1 (en)
AR (1) AR082024A1 (en)
TW (1) TW201206469A (en)
WO (1) WO2011161226A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090244A1 (en) * 2012-03-08 2014-10-29 Hoffmann La Roche FORMULATION OF ANTI-SELECTINE ANTIBODY P
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (en) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
SI3013318T1 (en) 2013-06-28 2017-11-30 Amgen Inc. Stable liquid formulation of amg 416 (velcalcetide)
BR112016003293A8 (en) 2013-08-30 2022-08-16 Takeda Gmbh GM-CSF NEUTRALIZING ANTIBODIES FOR USE IN THE TREATMENT OF RHEUMATOID ARTHRITIS OR AS ANALGESICS
HUE046767T2 (en) * 2014-03-31 2020-03-30 Hoffmann La Roche Anti-ox40 antibodies and methods of use
MX2016012779A (en) 2014-03-31 2017-04-27 Genentech Inc Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists.
ES2572919T3 (en) 2014-05-23 2016-06-03 Ares Trading S.A. Liquid pharmaceutical composition
PL2946765T3 (en) 2014-05-23 2017-08-31 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (en) 2014-05-23 2017-03-31 Ares Trading S.A. Liquid pharmaceutical composition
AU2016256911B2 (en) 2015-05-07 2022-03-31 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
SG10202008304TA (en) 2015-05-29 2020-10-29 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
CN108883173B (en) 2015-12-02 2022-09-06 阿吉纳斯公司 Antibodies and methods of use thereof
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3498263B1 (en) * 2016-08-10 2023-11-29 Celltrion Inc. Stable liquid pharmaceutical preparation for anti-influenza virus antibody
MA46770A (en) 2016-11-09 2019-09-18 Agenus Inc ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
CA3044664C (en) 2016-11-30 2022-11-22 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
KR20190142394A (en) * 2017-05-02 2019-12-26 머크 샤프 앤드 돔 코포레이션 Stable preparations of anti-TIGIT antibodies alone and in combination with programmed kill receptor 1 (PD-1) antibodies and methods of use thereof
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN110913906A (en) 2017-05-02 2020-03-24 默沙东公司 Formulations of anti-LAG 3 antibodies and co-formulations of anti-LAG 3 antibodies with anti-PD-1 antibodies
PE20212185A1 (en) 2019-02-18 2021-11-11 Lilly Co Eli FORMULATION OF THERAPEUTIC ANTIBODIES
MA55809A (en) * 2019-05-01 2022-03-09 Novo Nordisk As ANTI-IL-6 ANTIBODY FORMULATION
EP4151233A1 (en) * 2020-05-13 2023-03-22 Innovent Biologics (Suzhou) Co., Ltd. Preparation comprising anti-il-23p19 antibody, preparation method therefor and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2006029879A2 (en) * 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anti-ox40l antibodies
WO2006044908A2 (en) * 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
WO2007109221A2 (en) * 2006-03-20 2007-09-27 Wyeth Methods for reducing protein aggregation
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
WO2010059787A1 (en) * 2008-11-20 2010-05-27 Genentech, Inc. Therapeutic protein formulations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2006029879A2 (en) * 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anti-ox40l antibodies
WO2006044908A2 (en) * 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
WO2007109221A2 (en) * 2006-03-20 2007-09-27 Wyeth Methods for reducing protein aggregation
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
WO2010059787A1 (en) * 2008-11-20 2010-05-27 Genentech, Inc. Therapeutic protein formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG W ET AL: "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 96, no. 1, 1 January 2007 (2007-01-01), pages 1 - 26, XP009084505, ISSN: 0022-3549, DOI: 10.1002/JPS.20727 *

Also Published As

Publication number Publication date
WO2011161226A2 (en) 2011-12-29
AR082024A1 (en) 2012-11-07
TW201206469A (en) 2012-02-16
US20120128687A1 (en) 2012-05-24
EP2399604A1 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
WO2011161226A3 (en) Novel antibody formulation
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
WO2014028777A3 (en) Methods of treating a tauopathy
EP2668501A4 (en) Analyte detection devices, multiplex and tabletop devices for detection of analytes, and uses thereof
WO2011080209A3 (en) Antibody formulation
WO2011130615A3 (en) Preparation of lacosamide
TWI799757B (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
CL2013000912A1 (en) Liquid pharmaceutical formulation comprising anti-interleukin-4 receptor antibodies (il-4r).
WO2010031720A3 (en) Novel antibody formulation
WO2013177055A3 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
ECSP10010295A (en) FORMULATION OF ANTIBODY
MX336682B (en) Antibodies against human csf-1r and uses thereof.
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
WO2011088120A8 (en) Antibody formulation and therapeutic regimens
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
HUE037747T2 (en) Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
WO2011144674A3 (en) PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2650309A4 (en) Conjugate of folate and antibody, preparation method and use thereof
WO2012037184A3 (en) Mixing device
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
AU2013253581A8 (en) Anti-human CD69 antibody, and use thereof for medical purposes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11727181

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11727181

Country of ref document: EP

Kind code of ref document: A2